mRNA-1018-H5
Phase 3Recruiting 1 views this week 0 watching
0
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Influenza
Conditions
Influenza
Trial Timeline
Mar 23, 2026 → Jan 28, 2027
NCT ID
NCT07496450About mRNA-1018-H5
mRNA-1018-H5 is a phase 3 stage product being developed by Moderna for Influenza. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07496450. Target conditions include Influenza.
What happened to similar drugs?
20 of 20 similar drugs in Influenza were approved
Approved (20) Terminated (1) Active (0)
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07496450 | Phase 3 | Recruiting |
Competing Products
20 competing products in Influenza
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1010 | Moderna | Phase 1 | 0 |
| mRNA-1273 | Moderna | Phase 1 | 0 |
| mRNA-1010 | Moderna | Phase 2 | 0 |
| mRNA-1083 Composition 1 Dose A Lot A | Moderna | Phase 2 | 0 |
| mRNA-1010 | Moderna | Phase 3 | 0 |
| mRNA-1011.1 | Moderna | Phase 2 | 0 |
| mRNA-1083.1 | Moderna | Phase 2 | 0 |
| mRNA-1010 | Moderna | Phase 3 | 0 |
| mRNA-1083 | Moderna | Phase 3 | 0 |
| mRNA-1073 | Moderna | Phase 2 | 0 |
| VAL-506440 | Moderna | Phase 1 | 0 |
| mRNA-1083 | Moderna | Phase 3 | 0 |
| mRNA-1083 | Moderna | Phase 2 | 0 |
| mRNA-1010 | Moderna | Phase 3 | 0 |
| VAL-339851 | Moderna | Phase 1 | 0 |
| mRNA-1653 | Moderna | Phase 1 | 0 |
| mRNA-1030 | Moderna | Phase 2 | 0 |
| mRNA-1018 for H5N8 | Moderna | Phase 2 | 0 |
| mRNA-1653 | Moderna | Phase 1 | 0 |
| mRNA-1010 | Moderna | Phase 2 | 0 |